查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1596747

无菌注射剂市场：按分子类型、药物、适应症、分布划分 - 全球预测 2025-2030

Sterile Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug (Blood Factors, Cytokines, Immunoglobulins), Indication, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年无菌注射剂市值为5,184.9亿美元，预计2024年将达到5,686.2亿美元，复合年增长率为10.17%，到2030年将达到1,2181亿美元。

无菌注射剂是重要的药品，其设计不含活微生物，可确保经由肠胃外途径安全给药。这种需求源于快速有效地提供治疗的至关重要性，特别是在需要即时药物行动的情况下，例如紧急情况和手术。应用涵盖多种治疗领域，包括癌症、心血管疾病和感染疾病，最终用途主要在医院、诊所和门诊手术中心。市场成长的关键因素是慢性病的增加、生技药品的进步、药物传递系统的创新。向生物相似药的转变以及对客製化治疗的需求不断增加也增加了机会。对救生药物的监管支持也将提供进一步的推动力。然而，市场拓展面临严格法律规范、高製造成本、复杂製造流程等挑战。供应链中断和与低温运输要求相关的复杂物流进一步限制了成长。潜在的机会在于利用生技药品和标靶治疗的进步以及采用一次性系统和连续生物加工等创新製造技术来提高效率并降低成本。策略建议包括投资研发以提高药物稳定性和保质期，以及寻求伙伴关係以扩大市场。市场竞争的特征是大量的研究投入和严格的监管合规，要求企业专注于创新。智慧标籤和防篡改功能等包装创新标誌着差异化之路。最终，无菌注射剂市场具有强大的成长潜力，但必须策略性地应对监管挑战和供应链复杂性，以有效利用其中的新机会。平衡成本效率和高品质生产通讯协定被认为是维持业务成长和实现市场目标的关键。

主要市场统计
基准年[2023] 5184.9亿美元
预测年份 [2024] 5686.2亿美元
预测年份 [2030] 12,181亿美元
复合年增长率（%） 10.17%

市场动态：揭示快速发展的无菌注射剂市场的关键市场洞察

供需的动态交互作用正在改变无菌注射剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 人口中慢性病盛行率增加
    • 无菌注射剂的巨大好处和有效性
    • 增加医疗支出和改善医疗设施
  • 市场限制因素
    • 无菌注射药物生产高成本
  • 市场机会
    • 新配方和递送方法的开发
    • 扩建无菌注射药品生产设施
  • 市场问题
    • 严格的核准和认证流程

波特五力：驾驭无菌注射剂市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解无菌注射剂市场的外部影响

外部宏观环境因素在塑造无菌注射剂市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解无菌注射药物市场的竞争格局

对无菌注射剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：无菌注射剂市场供应商的绩效评估

FPNV定位矩阵是评估无菌注射剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划无菌注射剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对无菌注射剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人口中慢性病盛行率增加
      • 无菌注射剂的巨大好处和有效性
      • 医疗费用增加和医疗设施改善
    • 抑制因素
      • 製造无菌注射药物的高成本
    • 机会
      • 新製剂和给药方法的开发
      • 扩建无菌注射药品生产设施
    • 任务
      • 严格的核准和认证流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章无菌注射剂市场：依分子类型

  • 介绍
  • 高分子
  • 小分子

第七章 无菌注射剂市场：依药物分类

  • 介绍
  • 血液因素
  • 细胞激素
  • 免疫球蛋白
  • 胰岛素
  • 单株抗体 (mAb)
  • 肽激素
  • 疫苗

第八章无菌注射剂市场：依适应症分类

  • 介绍
  • 自体免疫疾病
  • 心血管和代谢疾病
  • 胃肠病学
  • 血液学
  • 感染疾病
  • 神经病学
  • 肿瘤学

第九章无菌注射剂市场：依分布

  • 介绍
  • 电子商务
  • 医院药房
  • 零售药房

第10章美洲无菌注射剂市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区无菌注射剂市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的无菌注射剂市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adare Pharma Solutions
  • Aenova Group
  • Almac Group
  • Avara Pharmaceutical Services, Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd
  • FAMAR Health Care Services
  • Fresenius Kabi Ag
  • Grifols SA
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Lonza
  • Nexus Pharmaceuticals, Inc.
  • Patheon, Inc.（Thermo Fischer）
  • Pfizer Inc.
  • Recipharm AB
  • Siegfried Holding AG
Product Code: MRR-F6513A06BE96

The Sterile Injectable Drugs Market was valued at USD 518.49 billion in 2023, expected to reach USD 568.62 billion in 2024, and is projected to grow at a CAGR of 10.17%, to USD 1,021.81 billion by 2030.

Sterile injectable drugs are crucial pharmaceutical products designed to be free from viable microorganisms, ensuring safe administration via parenteral routes. Their necessity stems from the critical need for rapid and efficient delivery of therapeutic agents, particularly in settings requiring immediate drug action, such as emergencies and surgeries. Applications span across various therapeutic domains, including oncology, cardiovascular diseases, and infectious diseases, with their end-use predominantly in hospitals, clinics, and ambulatory surgical centers. Market growth is primarily driven by increasing prevalence of chronic diseases, advancements in biologics, and innovation in drug delivery systems. The shift towards biosimilars and the growing demand for customized therapies also enhance opportunities. Regulatory support for life-saving medications provides an additional boost. However, market expansion faces challenges such as stringent regulatory frameworks, high costs of production, and complex manufacturing processes. Supply chain disruptions and the intricate logistics associated with cold chain requirements further constrain growth. Potential opportunities lie in leveraging advancements in biologic drugs and targeted therapies, as well as in adopting innovative manufacturing technologies like single-use systems and continuous bioprocessing to improve efficiency and reduce costs. Investing in R&D to enhance drug stability and shelf-life and exploring partnerships for market expansion stand as strategic recommendations. The competitive nature of the market, characterized by significant research investments and strict regulatory adherence, demands that companies focus on innovation. Innovations in packaging, such as smart labeling and tamper-evident features, offer avenues for differentiation. Ultimately, the sterile injectable drugs market, while marked by robust growth potential, requires strategic navigation of regulatory challenges and supply chain complexities to capitalize on emerging opportunities effectively. Balancing cost-efficiency with high-quality production protocols will be key to sustaining business growth and achieving market objectives.

KEY MARKET STATISTICS
Base Year [2023] USD 518.49 billion
Estimated Year [2024] USD 568.62 billion
Forecast Year [2030] USD 1,021.81 billion
CAGR (%) 10.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sterile Injectable Drugs Market

The Sterile Injectable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases among population
    • Significant benefits and efficacy of sterile injectable drugs
    • Rise in healthcare spending and improved healthcare facilities
  • Market Restraints
    • High costs associated with sterile injectable drug manufacturing
  • Market Opportunities
    • Development of novel formulations and delivery methods
    • Growing expansion of sterile injectable drug manufacturing facilities
  • Market Challenges
    • Stringent approval and certification processes

Porter's Five Forces: A Strategic Tool for Navigating the Sterile Injectable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sterile Injectable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sterile Injectable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sterile Injectable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sterile Injectable Drugs Market

A detailed market share analysis in the Sterile Injectable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sterile Injectable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sterile Injectable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sterile Injectable Drugs Market

A strategic analysis of the Sterile Injectable Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sterile Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Adare Pharma Solutions, Aenova Group, Almac Group, Avara Pharmaceutical Services, Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., CordenPharma, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd, FAMAR Health Care Services, Fresenius Kabi Ag, Grifols S.A., Hikma Pharmaceuticals PLC, Jubilant Pharmova Limited, Lonza, Nexus Pharmaceuticals, Inc., Patheon, Inc. (Thermo Fischer), Pfizer Inc., Recipharm AB, and Siegfried Holding AG.

Market Segmentation & Coverage

This research report categorizes the Sterile Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Large Molecule and Small Molecule.
  • Based on Drug, market is studied across Blood Factors, Cytokines, Immunoglobulins, Insulin, Monoclonal Antibodies (mAbs), Peptide Hormones, and Vaccine.
  • Based on Indication, market is studied across Autoimmune Diseases, Cardiovascular & Metabolic Diseases, Gastroenterology, Hematology, Infectious Diseases, Neurology, and Oncology.
  • Based on Distribution, market is studied across E-commerce, Hospital Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases among population
      • 5.1.1.2. Significant benefits and efficacy of sterile injectable drugs
      • 5.1.1.3. Rise in healthcare spending and improved healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with sterile injectable drug manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel formulations and delivery methods
      • 5.1.3.2. Growing expansion of sterile injectable drug manufacturing facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval and certification processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sterile Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Sterile Injectable Drugs Market, by Drug

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulins
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies (mAbs)
  • 7.7. Peptide Hormones
  • 7.8. Vaccine

8. Sterile Injectable Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cardiovascular & Metabolic Diseases
  • 8.4. Gastroenterology
  • 8.5. Hematology
  • 8.6. Infectious Diseases
  • 8.7. Neurology
  • 8.8. Oncology

9. Sterile Injectable Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. E-commerce
  • 9.3. Hospital Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Sterile Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sterile Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sterile Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adare Pharma Solutions
  • 2. Aenova Group
  • 3. Almac Group
  • 4. Avara Pharmaceutical Services, Inc.
  • 5. Baxter International Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Catalent, Inc.
  • 8. CordenPharma
  • 9. Eli Lilly and Company
  • 10. Evonik Industries AG
  • 11. F. Hoffmann-La Roche Ltd
  • 12. FAMAR Health Care Services
  • 13. Fresenius Kabi Ag
  • 14. Grifols S.A.
  • 15. Hikma Pharmaceuticals PLC
  • 16. Jubilant Pharmova Limited
  • 17. Lonza
  • 18. Nexus Pharmaceuticals, Inc.
  • 19. Patheon, Inc. (Thermo Fischer)
  • 20. Pfizer Inc.
  • 21. Recipharm AB
  • 22. Siegfried Holding AG

LIST OF FIGURES

  • FIGURE 1. STERILE INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. STERILE INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STERILE INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STERILE INJECTABLE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (MABS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 198. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023